Recently, poly(lactic acid)-PEG-Apt/Dox NPs have also developed as a tumor-targeting delivery system based on MUC1 aptamer-targeted nanoparticles for anticancer activity on the MUC1-overexpressing A-549 cell line (human alveolar basal epithelial cells) [112]. This evidence concerns the gene MUC1 and neoplasm.